跳至主導覽 跳至搜尋 跳過主要內容

Risks of dementia and stroke in patients with hypertension using telmisartan or other renin‐angiotensin system inhibitors

  • Chang Gung Memorial Hospital
  • Chang Gung University
  • National Taiwan University
  • New Taipei Municipal Tucheng Hospital

研究成果: 期刊稿件 › 文章 › 同儕審查

4 引文 斯高帕斯(Scopus)

摘要

INTRODUCTION: The aim of this study was to investigate the cognitive and cerebrovascular outcomes of patients with hypertension (HTN) receiving various renin-angiotensin system (RAS) inhibitors. METHODS: We further categorized 39,665 patients with HTN receiving long-term RAS inhibitor therapy into (1) telmisartan, (2) non-telmisartan angiotensin receptor blocker (NT-ARB), and (3) angiotensin-converting enzyme inhibitor groups. The main outcomes were a diagnosis of all dementias and the occurrence of all strokes during follow-up. RESULTS: The telmisartan group had the lowest risk of all dementias (telmisartan vs NT-ARB: hazard ratio [HR]: 0.78; 95% confidence interval [CI]: 0.60 to 1.01; telmisartan vs angiotensin-converting enzyme inhibitor: HR: 0.67; 95% CI: 0.48 to 0.94). The telmisartan group also had a lower risk of all strokes when compared to NT-ARB (HR: 0.78; 95% CI: 0.61 to 0.99) in the time-dependent cohort. DISCUSSION: Use of telmisartan may be associated with marginally lower risks of all dementias and strokes compared to other RAS inhibitors in patients with HTN. Highlights: Whether telmisartan is associated with a reduced risk of dementia compared to other RAS inhibitors in patients with HTN and varying blood sugar levels remains unclear. Our cohort study aimed to investigate the long-term cognitive and cerebrovascular outcomes of hypertensive patients receiving telmisartan compared to those receiving other RAS inhibitors. Eligible individuals were categorized into three groups. Use of telmisartan may be associated with marginally lower risks of all dementia and stroke compared with other RAS inhibitors in patients with HTN.

原文英語
文章編號e71153
頁(從 - 到)e71153
期刊Alzheimer's and Dementia
卷22
發行號2
DOIs
出版品狀態已出版 - 02 2026

文獻附註

© 2026 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Risks of dementia and stroke in patients with hypertension using telmisartan or other renin‐angiotensin system inhibitors」主題。共同形成了獨特的指紋。

引用此